Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.78 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.78 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.78 |
| ▸ | ANPEP | P15144 | 5/20 | 0.69 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366407 | 1.00 | DPP4 (0.78) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL29379602 | 0.90 | DPP4 (0.65) | DPP4NR1H2NR1H3ANPEPKMT2A | |
| SCHEMBL6927281 | 0.88 | DPP4 (1.00) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL17531021 | 0.87 | ANPEP (0.67) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL30954668 | 0.87 | ANPEP (0.67) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL29382416 | 0.87 | DPP4 (0.61) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL6925321 | 0.86 | ANPEP (0.66) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL300362 | 0.86 | DPP4 (0.61) | DPP4NR1H2NR1H3ANPEPKMT2A | |
| SCHEMBL24012151 | 0.84 | DPP4 (0.58) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL13990311 | 0.84 | DPP4 (0.58) | DPP4NR1H2NR1H3ANPEPFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10072346-A | — | — | None | — | — | JP | disclosed |
| CN-117466799-B | N-substituted phthalic acid diamide preparation method of imine compound | 西北师范大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-117466799-A | Preparation method of N-substituted phthalimide compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| WO-2016116525-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116487-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116528-A1 | SYMMETRICAL ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116530-A1 | COMPOSITIONS, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116527-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116520-A1 | PHENYLETHER-SUBSTITUTED ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016116521-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | CYNORA GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20080306134-A1 | THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES | CHARLESSON, LLC | 2008-12-11 | — | — | US | disclosed |
| US-6515129-B1 | A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): present invention relates to an aminopeptidase N inhibitor or an angiogenesis inhibitor, modulates production of tumor necrosis | ISHIHARA SANGYO KAISHA LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-6429212-B1 | AMINOPEPTIDASE N INHIBITOR USED TO TREAT CANCER, TUMORS, AND RETINOPATHY; FEW SIDE EFFECTS; ANGIOGENESIS INHIBITOR | ISHIHARA SANGYO KAISHA LTD. (JP) | 2002-08-06 | — | — | US | disclosed |
| JP-H1072346-A | TUMOR NECROSIS FACTOR PRODUCTION-INHIBITING MEDICINE OR VASCULARIZATION-INHIBITING MEDICINE CONTAINING N-PHENYLPHTHALIMIDE DERIVATIVE | ISHIHARA SANGYO KAISHA LTD | 1998-03-17 | — | — | JP | disclosed |
| EP-0245989-B1 | FLUOROPHTHALIMIDES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1991-07-10 | — | — | EP | disclosed |
| US-4839378-A | FOR CONTROLLING PLANT DISEASES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0245989-A2 | Fluorophthalimides | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | SLC2A8, VEGFA, SLC2A1 | DPP4 35/4885NR1H2 4642/4885NR1H3 4661/4885 |
| US-20080306134-A1 | THALIDOMIDE ANALOGS FOR TREATING VASCULAR ABNORMALITIES | VEGFA, FLT1, VCAM1 | DPP4 4355/4885NR1H2 4128/4885NR1H3 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.